Ratio Review: Analyzing Cue Biopharma Inc (CUE)’s Price-to-Cash and Price-to-Free Cash Flow

The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

After finishing at $1.28 in the prior trading day, Cue Biopharma Inc (NASDAQ: CUE) closed at $1.31, up 2.34%. In other words, the price has increased by $2.34 from its previous closing price. On the day, 0.2 million shares were traded. CUE stock price reached its highest trading level at $1.32 during the session, while it also had its lowest trading level at $1.22.

Ratios:

Our goal is to gain a better understanding of CUE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.22 and its Current Ratio is at 2.22. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.10.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 13, 2024, initiated with a Buy rating and assigned the stock a target price of $6.

On November 21, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $7.Piper Sandler initiated its Overweight rating on November 21, 2022, with a $7 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 ’24 when PASSERI DANIEL R bought 30,000 shares for $1.03 per share. The transaction valued at 30,900 led to the insider holds 164,578 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CUE now has a Market Capitalization of 82988888 and an Enterprise Value of 41794928. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.71 while its Price-to-Book (P/B) ratio in mrq is 3.11. Its current Enterprise Value per Revenue stands at 5.039 whereas that against EBITDA is -0.876.

Stock Price History:

The Beta on a monthly basis for CUE is 1.63, which has changed by -0.5387324 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, CUE has reached a high of $3.03, while it has fallen to a 52-week low of $0.45. The 50-Day Moving Average of the stock is 5.43%, while the 200-Day Moving Average is calculated to be 8.40%.

Shares Statistics:

The stock has traded on average 584.25K shares per day over the past 3-months and 477640 shares per day over the last 10 days, according to various share statistics. A total of 63.35M shares are outstanding, with a floating share count of 62.87M. Insiders hold about 0.75% of the company’s shares, while institutions hold 23.54% stake in the company. Shares short for CUE as of 1730332800 were 1780964 with a Short Ratio of 2.23, compared to 1727654400 on 3800384. Therefore, it implies a Short% of Shares Outstanding of 1780964 and a Short% of Float of 2.98.

Most Popular